Lübbert M - Search Results

1

Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.

Gröschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kühn MW, Eiwen K, Erpelinck C, Havermans M, Lübbert M, Germing U, Schmidt-Wolf IG, Beverloo HB, Schuurhuis GJ, Ossenkoppele GJ, Schlegelberger B, Verdonck LF, Vellenga E, Verhoef G, Vandenberghe P, Pabst T, Bargetzi M, Krauter J, Ganser A, Valk PJ, Löwenberg B, Döhner K, Döhner H, Delwel R. Gröschel S, et al. Among authors: lubbert m. J Clin Oncol. 2013 Jan 1;31(1):95-103. doi: 10.1200/JCO.2011.41.5505. Epub 2012 Sep 24. J Clin Oncol. 2013. PMID: 23008312

2

A switch toward demethylation is associated with the expression of myeloperoxidase in acute myeloblastic and promyelocytic leukemias.

Lübbert M, Oster W, Ludwig WD, Ganser A, Mertelsmann R, Herrmann F. Lübbert M, et al. Blood. 1992 Oct 15;80(8):2066-73. Blood. 1992. PMID: 1327288 Free article.

3

Detection of karyotypic aberrations in acute myeloblastic leukaemia: a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML.

Krauter J, Peter W, Pascheberg U, Heinze B, Bergmann L, Hoelzer D, Lübbert M, Schlimok G, Arnold R, Kirchner H, Port M, Ganser A, Heil G. Krauter J, et al. Among authors: lubbert m. Br J Haematol. 1998 Oct;103(1):72-8. doi: 10.1046/j.1365-2141.1998.00926.x. Br J Haematol. 1998. PMID: 9792292 Free article.

4

Association between structural and numerical chromosomal aberrations in acute myeloblastic leukemia: a study by RT-PCR and FISH in 447 patients with de-novo AML.

Krauter J, Ganser A, Bergmann L, Raghavachar A, Hoelzer D, Lübbert M, Schlimok G, Arnold R, Kirchner H, Port M, Heil G. Krauter J, et al. Among authors: lubbert m. Ann Hematol. 1999 Jun;78(6):265-9. doi: 10.1007/s002770050512. Ann Hematol. 1999. PMID: 10422628

5

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.

Wijermans P, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A. Wijermans P, et al. Among authors: lubbert m. J Clin Oncol. 2000 Mar;18(5):956-62. doi: 10.1200/JCO.2000.18.5.956. J Clin Oncol. 2000. PMID: 10694544 Clinical Trial.

6

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.

Lübbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A. Lübbert M, et al. Br J Haematol. 2001 Aug;114(2):349-57. doi: 10.1046/j.1365-2141.2001.02933.x. Br J Haematol. 2001. PMID: 11529854 Free article.

7

Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.

Krauter J, Gorlich K, Ottmann O, Lubbert M, Dohner H, Heit W, Kanz L, Ganser A, Heil G. Krauter J, et al. Among authors: lubbert m. J Clin Oncol. 2003 Dec 1;21(23):4413-22. doi: 10.1200/JCO.2003.03.166. J Clin Oncol. 2003. PMID: 14645432

8

Risk-adapted induction and consolidation therapy in adults with de novo AML aged </= 60 years: results of a prospective multicenter trial.

Heil G, Krauter J, Raghavachar A, Bergmann L, Hoelzer D, Fiedler W, Lübbert M, Noens L, Schlimok G, Arnold R, Kirchner H, Ganser A. Heil G, et al. Among authors: lubbert m. Ann Hematol. 2004 Jun;83(6):336-44. doi: 10.1007/s00277-004-0853-z. Epub 2004 Mar 18. Ann Hematol. 2004. PMID: 15034758 Clinical Trial.

9

Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study.

Giagounidis AA, Haase S, Germing U, Schlegelberger B, Wilkens L, Büsche G, Kreipe HH, Wysk J, Grips KH, Grabenhorst U, Rothmann F, Lübbert M, Ganser A, Aivado M, Heinsch M, Aul C. Giagounidis AA, et al. Among authors: lubbert m. Ann Hematol. 2005 Jun;84(6):389-94. doi: 10.1007/s00277-005-1027-3. Epub 2005 Mar 23. Ann Hematol. 2005. PMID: 15785949 Clinical Trial.

10

Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instability.

Haas PS, Wijermans P, Verhoef G, Lübbert M. Haas PS, et al. Among authors: lubbert m. Leuk Res. 2006 Mar;30(3):338-42. doi: 10.1016/j.leukres.2005.07.014. Epub 2005 Sep 12. Leuk Res. 2006. PMID: 16162357 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

359 results

Search Page